Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that Inovio’s Chief Executive Officer, Dr. J. Joseph Kim, has been selected as the “Entrepreneur of the Year™” for Greater Philadelphia by Ernst & Young, a global leader in assurance, tax, and advisory services.
Dr. Kim, who co-founded the organization that became Inovio Pharmaceuticals, was recognized for his vision, passion, medical and financial acumen in building Inovio from a two-person start-up into a clinical-stage publicly traded immunotherapy company with innovative therapies for cancers and infectious diseases.
Last year, Inovio reported a medical breakthrough by demonstrating the first clinically meaningful efficacy results from T cells generated exclusively in vivo in the history of its DNA based immunotherapy technology. These results were from a phase II study treating cervical pre-cancer. Early next year, Inovio will move this lead product into phase III. The company has also received more than $70 million in government grants in the past eight months to develop HIV, influenza and Ebola treatments and vaccines.
Dr. Kim said, “I thank Ernst & Young for this honor and for the input from family, friends, employees and business advisors who supported me and my vision to build a company that is striving to create safe and effective immunotherapies to help patients and their families beat cancer.”
E&Y’s Entrepreneur of the Year is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur of the Year celebrates those who are building and leading successful, growing and dynamic businesses. (Original Source)
Shares of Inovio Pharmaceuticals closed yesterday at $8.93. INO has a 1-year high of $13.04 and a 1-year low of $6.33. The stock’s 50-day moving average is $8.62 and its 200-day moving average is $8.59.
On the ratings front, Inovio has been the subject of a number of recent research reports. In a report issued on May 11, Brean Murray Carret analyst Jonathan Aschoff reiterated a Buy rating on INO, with a price target of $20, which represents a potential upside of 124.0% from where the stock is currently trading. Separately, on March 12, H.C. Wainwright’s Yi Chen initiated coverage with a Buy rating on the stock and has a price target of $17.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jonathan Aschoff and Yi Chen have a total average return of 10.8% and 6.1% respectively. Aschoff has a success rate of 55.1% and is ranked #246 out of 3623 analysts, while Chen has a success rate of 66.7% and is ranked #1713.
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.